PHLDA3 exerts an antitumor function in prostate cancer by down-regulating Wnt/β-catenin pathway via inhibition of Akt-Reference-Cited by-同舟云学术

PHLDA3 exerts an antitumor function in prostate cancer by down-regulating Wnt/β-catenin pathway via inhibition of Akt

Published:2021-09 Issue: Volume:571 Page:66-73
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Ma Shuaijun,Quan Penghe,Yu Changjiang,Fan Xiaozheng,Yang Shuhan,Jia Weijing,Zhang Longlong,Wang Fuli,Liu Fei,Yang Lijun,Qin Weijun,Yang Xiaojian^ORCID

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference28 articles.

1. Cancer statistics, 2020;Siegel;Ca - Cancer J. Clin.,2020

2. Cancer treatment and survivorship statistics;Miller;Ca - Cancer J. Clin.,2019

3. Epigenetic mechanisms in the biology of prostate cancer;Schulz;Semin. Canc. Biol.,2009

4. Epigenomic regulation of androgen receptor signaling: potential role in prostate cancer therapy;Cucchiara;Cancers,2017

5. p53-PHLDA3-Akt network: the key regulators of neuroendocrine tumorigenesis;Chen;Int. J. Mol. Sci.,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging role of non-coding RNAs in the Wnt/β-catenin signaling pathway in Prostate Cancer;Pathology - Research and Practice;2024-02

2. Enhancer regulatory networks globally connect non-coding breast cancer loci to cancer genes;2023-11-20

3. PHLDA3 activated by BARX2 transcription, suppresses the malignant development of esophageal squamous cell carcinoma by downregulating PI3K/AKT levels;Experimental Cell Research;2023-05

4. Targeting PI3K/Akt signaling in prostate cancer therapy;Journal of Cell Communication and Signaling;2022-11-11

5. Pleckstrin homology-like domain family A, member 3, a miR-19a-3p-regulated gene, suppresses tumor growth in osteosarcoma by downregulating the Akt pathway;Bioengineered;2022-02-01